In addition, the combined expression of HAS2-HYAL1 detected bladder cancer with overall sensitivity of 85.4% and 79.5% specificity, predicting recurrence within 6 months [179] (Figure 6). Here, HYAL1 is linked to urinary bladder carcinoma.